Global Virus Network (GVN) Elects New Board Members and Welcomes New Senior Advisors

Global Virus Network (GVN) Elects New Board Members and Welcomes New Senior Advisors

Global Virus NetworkNora Grannell, 410-706-1966

The Global Virus Network (GVN), a coalition of the world’s leading medical virology research centers comprising 31 GVN Centers of Excellence in 25 nations working to prevent illness and death from viral disease, today announced the addition of four members to its Board of Directors, including Mary Jane Gallo, a long-time, ardent supporter of biomedical research, particularly as related to combatting HIV/AIDS and other infectious diseases ; Glenda Gray, MBBCh, FCPAED, President of the Medical Research Council of South Africa ; William Kirwan, PhD, Chancellor of the University System of Maryland; Raymond Schinazi, PhD, Hon DSc, Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University; and, two Senior Advisors, Prudence Bushnell, Ambassador (Ret.), CEO of Sage Associates and Founder of the Levitt Leadership Institute at Hamilton College; and, Neal Lane, former Science Advisor to the U.S. President, Senior Fellow in science and technology policy at the Baker Institute and Professor of the Department of Physics and Astronomy at Rice University. The was made today by Robert Gallo, MD, GVN Co-Founder and Director of the Institute of Human Virology at the University of Maryland School of Medicine, William Hall, MD, PhD, GVN Co-Founder and Director of the Centre for Research in Infectious Diseases at University College Dublin, and Tim Moynahan, Chair of the GVN Board of Directors and Founder of The Moynahan Law Firm, LLC.

“As GVN continues to grow, these new board members and senior advisors will enhance GVN’s global reach and help GVN realize its mission to advance research on all viral diseases, including those with pandemic potential; to train the next generation of medical virologists; to educate the public on viral threats and scientific responses; and, to advocate for support for the medical virology field,” said Dr. Gallo.

“We look forward to building on our success from this past year and welcome each of these strong leaders to advance our cause in 2015 and beyond,” said Mr. Moynahan.

GVN was co-founded by Dr. Robert Gallo, the late Dr. Reinhard Kurth of Germany, and Dr. William Hall, joined by noted medical virologists from around the world. Dr. Gallo noted at the time of GVN’s launch in 2011 that “the world should never again be as unprepared in the face of a new virus as we were when AIDS struck.” Today, the GVN coalition is a vital safety net against the spread of new viruses even as it tackles well-known killers, including Ebola, influenza, hepatitis, HIV, measles, enteroviruses, and others. GVN works increasingly with strategic partners, including the World Health Organization; national public health agencies, including the U.S. Centers for Disease Control and Prevention (CDC), medical research funding agencies, including the U.S. National Institutes of Health (NIH) and the Pasteur Institute; foundations; pharmaceutical companies and other corporate entities, in part through a newly launched Business Leadership Council. GVN scientists are located in the following countries: Argentina, Australia, Belgium, Brazil, China, Estonia, France, Germany, Grenada, India, Ireland, Israel, Italy, Japan, Lebanon, Netherlands, Nigeria, Russia, South Africa, Spain, Sweden, United Kingdom, United States and Vietnam.

For biographies on the new members and advisors please .